Introduction
Insomnia is characterized by difficulties in sleep initiation and sleep maintenance and by poor sleep quality, resulting in impairment of daytime function. It is the most common subjective sleep difficulty in anxious and depressed patients (Winokur et al., 2001; Buckner et al., 2008) . Approximately 80% of hospitalized depressed patients also have objective alterations in sleep EEG patterns (Winokur et al., 2001) . Diazepam and zolpidem are used to treat insomnia in humans. These compounds significantly increase total nonrapid eye movement (non-REM, NREM) sleep time, but they also cause a remarkable decrease in delta activity during NREM sleep (van Lier et al., 2004) . The discrepancy between the increase in sleep continuity and the reduction of power in the lower EEG frequencies caused by benzodiazepines in humans is consistent with the findings in mice (Tobler et al., 2001) . It is well known that benzodiazepines have many untoward reactions, such as drug dependence, tolerance, rebound insomnia, amnesia and muscle relaxation (Vgontzas et al., 1995; Aragona, 2000) . Therefore, we need sleeppromoting compounds that induce physiological sleep without significant adverse effects.
Honokiol (5,3′-diallyl-2,4′-dihydroxybiphenyl, C18H18O2; for chemical structure, see Figure 1 ) is an active component of the Chinese herb houpo (Teng et al., 1988) . Decoctions of houpu, a traditional Chinese medicinal formula containing honokiol, is used to treat depression effectively in China (Ding, 1992; Li and Kong, 2001) . Honokiol extends the time spent in the open arms of the maze in mice, and this anxiolytic effect is inhibited by flumazenil, an antagonist at the benzodiazepine site of the GABAA receptor (Kuribara et al., 1998; 2000 ; receptor nomenclature follows Alexander et al., 2011) . A mixture of honokiol and magnolol, an isomer of honokiol, possesses an antidepressant-like effect in the forced swimming test and chronic mild stress in rodents . Because attenuation of depression and anxiety can improve sleep quality, these results can be interpreted to mean that honokiol may promote sleep.
In the present study, we administered honokiol, by a single i.p. injection, to mice during the active period and characterized their sleep-wake behaviour by recording EEGs and electromyograms (EMG). We also examined the effects of flumazenil on the honokiol-induced sleep. In addition, c-Fos immunostaining and whole-cell patch clamping in brain slices were used to explore the mechanisms involved in the sleep-promoting effects of honokiol. Our findings indicate that honokiol promoted NREM sleep via the benzodiazepine site of the GABAA receptor, suggesting that it may have applications in the treatment of insomnia.
Methods

Animals
All animal care and experimental protocols were approved by the Medical Experimental Animal Administrative Committee of Shanghai. Every effort was made to minimize the number of animals used and any pain and discomfort that they might experience. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (McGrath et al., 2010) . Male C57BL/6 J mice (20-26 g; 11-13 weeks old), and post-natal Sprague-Dawley rats (14-21 days old) were obtained from the Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). The animals were housed in an insulated, sound-proof recording room maintained at an ambient temperature of 22 Ϯ 0.5°C, with a relative humidity (60 Ϯ 2%) on an automatically controlled 12 h light/12 h dark cycle (lights on at 8:00). They had free access to food and water. A total of 84 mice and 23 rats were used in the experiments reported here.
Pharmacological treatments
Honokiol (Wako Pure Chemicals, Osaka, Japan) was dissolved in sterile saline containing 10% DMSO immediately before use and administered i.p. at 20:00 on the experimental day at doses of 5, 10 or 20 mg·kg . Diazepam (Tianjin Pharmaceutical Co., Ltd. Tianjin, China) at 6 mg·kg -1 was diluted with sterile saline immediately before use and administered i.p. at 20:00 on the experimental day. Flumazenil (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in sterile saline and administered i.p. 15 min before the injection of honokiol. For baseline data, mice were injected i.p. with vehicle (saline containing 10% DMSO) at 19:45 and 20:00. (-)-Noradrenaline (Sigma-Aldrich) was diluted in fresh artificial cerebrospinal fluid (ACSF; composition see below) to the final concentration immediately before the experiment of wholecell patch-clamp studies.
Polygraphic recordings and vigilance state analysis
Under pentobarbital anaesthesia (50 mg·kg -1 , i.p.), the mice were chronically implanted with EEG and EMG electrodes for polysomnographic recordings. The implant consisted of two stainless steel screws (1 mm diameter) inserted through the skull of the cortex (anteroposterior, +1.0 mm and left-right, -1.5 mm from bregma or lambda) according to the atlas of Franklin and Paxinos (1997) . These served as EEG electrodes. Two insulated, stainless steel, Teflon-coated wires were placed bilaterally into both trapezius muscles. These served as EMG electrodes. All electrodes were attached to a micro-connector and fixed to the skull with dental cement.
The EEG and EMG recordings were carried out by means of a slip ring designed so that the behavioural movement of the mice would not be restricted. After a 10 day recovery period, the mice were housed individually in transparent barrels and habituated to the recording cable for 3-4 days prior to polygraphic recording. Sleep-wakefulness states were monitored for a period of 48 h, which comprised baseline and experimental days. Baseline recordings were taken in each animal for 24 h, beginning at 08:00 h. These served as controls for the same animal.
Figure 1
The chemical structure of honokiol.
Cortical EEG and EMG signals were amplified and filtered (EEG, EMG, and then digitized at a sampling rate of 128 Hz and recorded by using SleepSign (Kissei Comtec, Nagano, Japan) as described previously Qiu et al., 2009) . When complete, polygraphic recordings were automatically scored off-line by 10 s epochs as wakefulness, REM and NREM sleep by SleepSign according to the standard criteria Oishi et al., 2008; Qu et al., 2010; Yan et al., 2011) . As a final step, defined sleep-wake stages were examined visually and corrected if necessary.
c-Fos immunohistochemistry
Six groups of mice were used. One group was treated with vehicle and the others were injected i.p. with honokiol at doses of 5, 10 or 20 mg·kg . To test the receptor mechanisms, two groups of mice were used. Flumazenil (1 mg·kg -1 ) was given 15 min before the honokiol (20 mg·kg -1 ) or vehicle injection. Two hours after receiving a test dose of honokiol, the animals received deep anaesthesia with chloral hydrate (350 mg·kg -1 , i.p.) and were immediately perfused transcardially with 200 mL of saline, followed by 200 mL of 4% formalin. The brain was removed, post-fixed for 24 h at 4°C in 4% formalin and then equilibrated in phosphate buffer containing 30% sucrose for 24 h at 4°C. Coronal sections (30 mm) were cut serially on a cryostat.
Immunohistochemistry was performed in accordance with the free-floating method described earlier (Qiu et al., 2003; 2009; Chen et al., 2011) . Sections were washed with PBS (three changes) and incubated in PBS containing 0.25% Triton X-100 at room temperature and then incubated at 4°C for 24 h with a rabbit polyclonal antibody against c-Fos (1:20 000, Calbiochem, Merck KGaA, Darmstadt, Germany) diluted in PBS containing 0.25% Triton X-100. Sections were then washed and incubated in biotinylated anti-rabbit IgG antibody (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), washed again with PBS and incubated in avidinbiotin complex reagents at room temperature for 1 h (1:200; Santa Cruz Biotechnology, Inc.). Sections were then washed again and incubated in a solution of 0.05% 3,3-diaminobenzidine (Sigma) plus 0.03% H2O2. All sections were mounted onto gelatin-coated slides, dehydrated in graded ethanol, placed into xylenes, and coverslipped. As controls, adjacent sections were incubated without primary antibody to confirm that no non-specific staining had occurred.
The sections were examined under bright-field illumination with a Leica DMLB microscope (Leica Microsystems, Wetzlar, Germany). Images were captured with a CoolSNAPProcf digital camera (RTKE Diagnostic, Spot Instruments, Sterling Heights, MI, USA). Using light microscopy, neurons positive for c-Fos were identified by their characteristic dense brown nuclear staining. Locations in the brain were confirmed by staining and reference to the primary literature and a mouse brain atlas. Four sections through the middle of each structure per animal were counted (by technicians unaware of the treatments) and averaged.
Electrophysiological experiments
Preparation of brain slices. Electrophysiological experiments were performed on slices retrieved from post-natal SpragueDawley rats that were 14-21 days old. The hypothalamic slices were prepared as described previously (Gallopin et al., 2000) . Briefly, Sprague-Dawley rats were killed by decapitation. The ventrolateral preoptic area (VLPO) was identified according to the stereotaxic coordinates (Paxinos and Watson, 1997) . Coronal midbrain slices (300 mm thick) containing VLPO were cut using a vibratome (Leica VT 1000 S) in ice-cold glycerol-based artificial cerebrospinal fluid (GACSF) containing (in mM): glycerol (260), KCl (5), KH 2PO4 (1.25), MgSO4 (1.3), CaCl2 (0.5), NaHCO3 (20) and glucose (10), and saturated with 95% O2-5% CO2 (carbogen). Slices were allowed to recover for at least 1 h in a holding chamber at room temperature (32°C) in a carbogen-saturated normal ACSF (composition (in mM): NaCl (125), KCl (5), KH2PO4 (1.25), MgSO4 (1.3), CaCl2 (2.4), NaHCO3 (20) and glucose (10). Note this has the same composition as GACSF, except that glycerol was replaced by 125 mM NaCl, and that the concentration of CaCl2 was adjusted to 2.4 mM.
Extracellular recordings in loosely cell-attached configuration.
This recording configuration was used to study the effects of multiple drug applications on a single VLPO cell. In contrast to intracellular and whole-cell patch-clamp configurations, this mode allows stable extracellular recordings of healthy neurons for the long periods of time necessary to complete pharmacological experiments, including synaptic uncoupling conditions (low Ca 2+ /high Mg 2+ ). Infrared differential interference contrast videomicroscopy was used to locate the sleep neurons in the VLPO according to their triangular and multipolar shape as reported previously (Gallopin et al., 2000) . Recordings of the numbers of loosely attached cells in the soma were made using patch micropipettes (5-8 MÙ) pulled from borosilicate glass capillaries (1.5 mm o.d., 0.86 mm i.d.; Harvard Apparatus, Les Ulis Cedex, France) on a Brown-Flaming micropipette puller (Model P-97, Sutter Instrument, Novato, CA, USA). The micropipettes, filled with ACSF, were attached to an electric microdrive (Luigs and Neumann, Ratingen, Germany) and placed under visual control in contact with the soma of the selected cell. During extracellular recordings of the loosely cell-attached configuration, a seal resistance of 10-15 MÙ was maintained to avoid damage or mechanical stimulation to the cell.
In whole-cell and cell-attached configurations, electrical signals were obtained using an Axon 200B amplifier, a Digidata 1440A A/D converter and pCLAMP 10.2 software (Molecular Devices Co., Union City, CA, USA). Data were filtered at 1 kHz and sampled at 5 kHz.
Data analysis
All results are expressed as means Ϯ SEM. For the time-course data, the different numbers of the different sleep-wake states were analysed using the paired t-test, with each animal serving as its own control. For the total numbers of each vigilance stage during the 4 h immediately following drug treatment and the number of c-Fos immunoreactive neurons, one-way repeated measures ANOVA was performed, followed by Fisher's probable least-squares difference (PLSD) test to determine whether the difference among groups was statistically significant. In all cases, P < 0.05 was taken as the level of significance.
Results
Effects of honokiol on NREM sleep in mice
To determine the effects of honokiol on sleep-wake profiles, honokiol was injected i.p. into C57BL/6 mice at 20:00 h at doses of 5, 10 or 20 mg·kg -1 , and diazepam was given at 6 mg·kg -1 as a positive control. A greater difference in the sleep-wake cycle was observed between the injection of vehicle and honokiol (20 mg·kg -1 ). Typical examples of polygraphic recordings and corresponding hypnograms illustrated the effects of honokiol on sleep-wake profiles from an individual mouse (Figure 2A,B) . During the period from 20:00 h to 0:00 h, this mouse spent more time in wakefulness when under vehicle control than when given honokiol ( Figure 2A ). When honokiol was injected on the experimental day, however, the animal spent more time asleep than it had while its control values were being recorded ( Figure 2B ). The latency to NREM sleep, which is defined as the time from injection to the appearance of the first NREM sleep episode lasting for at least 20 s, was 26.8 min in the mice treated with honokiol at 20 mg·kg
. This is significantly shorter than 63.3 min for the latency in mice after vehicle injection ( Figure 2C ). The short sleep latency observed in honokiolinjected mice indicates that honokiol accelerates the initiation of NREM sleep.
Time-course changes in NREM sleep showed that the sleep-promoting effects of honokiol at 20 mg·kg -1 lasted for 4 h. Honokiol is compared with the vehicle control in Figure 2D , it increased the amount of NREM sleep during the first, second, third and fourth hours by 3-, 5.4-, 4.3-and 2.8-fold, respectively. This enhancement of NREM sleep was accompanied by a decrease in wakefulness. However, REM sleep did not change after the administration of honokiol. There was no further disruption of the sleep architecture during the subsequent period. Similar time-course profiles were observed at the lower dose of 10 mg·kg -1 , but the effect on sleep was slighter, lasting about 2 h after the injection. Honokiol at 5 mg·kg -1 did not affect the sleep profiles (data not shown).
We calculated the total amount of NREM and REM sleep and wakefulness during the 4 h immediately following administration. Honokiol at doses of 10 and 20 mg·kg -1 was found to increase NREM sleep by 2.5-and 3.8-fold and to decrease the total amount of wakefulness by 27% and 43%, respectively, as compared with the baseline values ( Figure 2E ). Honokiol given at 5 mg·kg -1 did not affect the amounts of NREM sleep and wakefulness for 4 h postinjection. ANOVA revealed that honokiol increased NREM sleep [F(3,20) = 15.5, P < 0.01]. The effect of honokiol at 20 mg·kg -1 was stronger than those of honokiol at 5 and 10 mg·kg -1 but not significantly different from that of diazepam at 6 mg·kg -1 (P > 0.05, PLSD). There was no essentially significant difference in REM sleep after the administration of honokiol at the three dosage levels tested. These results clearly revealed that honokiol increased NREM sleep with concomitant reduction in wakefulness in a dosedependent manner, but did not alter REM sleep in mice.
Diazepam at 6 mg·kg -1 increased the total amounts of NREM sleep by 4.1-fold and decreased wakefulness by 41%, during that 4 h period, relative to the vehicle control ( Figure 2E ). However, there was no significant difference in REM sleep for 4 h after injection between diazepam and its vehicle control.
Effects of flumazenil on the sleep-promoting effects of honokiol
To determine whether the GABAergic system might be involved in the somnogenic effects of honokiol, honokioltreated mice were pretreated with flumazenil, a selective antagonist at the benzodiazepine site of GABAA receptor. Flumazenil (1 mg·kg -1 ) alone showed no significant effects on sleep latency or total amounts of sleep (data not shown). Honokiol increased the amount of NREM sleep by 2.4-fold during the first 4 h after administration. In contrast, pretreatment with flumazenil completely abolished the somnogenic effect of honokiol ( Figure 3A,B) . These results indicate that the induction of sleep caused by honokiol is modulated by the benzodiazepine site of the GABAA receptor.
Effects of honokiol on characteristics of sleep-wake episodes and power density
To better understand the sleep-wake profile caused by honokiol, we determined the total number and mean duration of NREM and REM sleep, and wake episodes. As shown in Figure 4A , honokiol at 20 mg·kg -1 increased the number of NREM bouts by 4.4-fold and wake episodes by 4.2-fold, but the mean duration of NREM and REM sleep was not altered during the 4 h period after the injection. The mean duration of episodes of wakefulness was significantly decreased by 83% after honokiol injection.
In addition, honokiol at 20 mg·kg -1 increased NREM sleep and wake bouts relative to the vehicle control. These bouts ranged from 0 to 240 s and from 10 to 480 s, respectively ( Figure 4C ), whereas the longer duration of NREM sleep and wakefulness was not altered after honokiol injection. In contrast, REM sleep bouts did not change after administration of honokiol (data not shown).
As a result, the numbers of state transitions from wakefulness (W) to NREM sleep (N) and from N to W were increased after the injection with honokiol ( Figure 5A ). However, no change in either the number of transitions from N to REM (R) or that from R to W was observed.
Honokiol changed the number and durations of episodes of wakefulness and NREM sleep and the transitions between these two states. These alterations were completely abolished by flumazenil ( Figures 4B,D and 5B,D), supporting the conclusion that honokiol promotes sleep via the benzodiazepine site of the GABAA receptor.
Seeing that honokiol increased NREM sleep, we determined the EEG power spectra of NREM sleep in mice. As shown in Figure 5C , there were no significant differences in the EEG power density of NREM sleep between honokiol treatment and vehicle control, indicating that honokiol did not affect the EEG power density of NREM sleep. These results suggest that honokiol induces NREM sleep very similar to physiological NREM sleep.
Effects of honokiol on c-Fos expression in the VLPO and tuberomammillary nucleus (TMN)
To study the effects of honokiol on the VLPO sleep centre and the histaminergic TMN arousal centre, we investigated the number of c-Fos immunoreactive neurons in these areas after honokiol treatment. The VLPO consists of the VLPO cluster, just lateral to the optic chiasma, and the extended VLPO that extends dorsally and medially from this cluster (Lu et al., 2000) . VLPO cluster by 3.6-and 6.3-fold [ Figure 6I , F(3,19) = 16.944, P < 0.01], respectively, relative to the vehicle control. Fospositive neurons in the extended VLPO were also increased from 7.1 Ϯ 1.4 to 16.8 Ϯ 1.7 (P < 0.01) and 35.5 Ϯ 2.6 (P < 0.01) after treatment of honokiol at 10 and 20 mg·kg Figure 6I , F(3,31) = 7.188, P < 0.01], respectively, relative to the vehicle control. These findings indicate that honokiol activates the VLPO sleep centre and inhibits the activity of the TMN arousal system. Figure 6E -H shows composite drawings of representative photomicrographs of c-Fos expression in the VLPO and TMN in mice pretreated with flumazenil at 1 mg·kg 
Effects of flumazenil on increased c-Fos immunoreactivity induced by honokiol in the VLPO
Effects of honokiol on the firing rate of VLPO sleep-promoting neurons in in vitro brain slices
Electrophysiological experiments were conducted in acute brain slices. As shown in Figure 7A , the majority of cells within the VLPO were triangular and multipolar in shape. In the cell-attached configuration, the sleep-promoting neurons were inhibited by a brief application (50 s) of noradrenaline (10 mM) ( Figure 7B ), as shown earlier by Gallopin et al., (2000) .
To determine the effects of honokiol on the activity of VLPO sleep-promoting neurons in acute brain slice of rat, loosely attached cells were employed under current-clamp mode. The sleep-promoting neurons were identified accord- ing to the inhibitory effect of noradrenaline on the firing rate. Bath application of honokiol to acute brain slices excited the majority of VLPO neurons, which were inhibited by noradrenaline. Honokiol at concentrations of 100 and 300 mM increased the firing rate of VLPO sleep-promoting neurons [F(2,27) = 5.215, P < 0.05] by 47% and 84% respectively ( Figure 7C,D) . These results suggest that honokiol can increase the firing rate of sleep-promoting neurons.
Discussion
In the present study, we found that honokiol increased the total duration of NREM sleep but did not change the EEG power density of NREM sleep. EEG delta activity is an indicator of the depth of NREM sleep (Tobler et al., 2001) . In humans and rodents, benzodiazepines significantly decrease the total duration of wakefulness and increase the total duration of NREM sleep, but typically reduce EEG delta activity in NREM sleep (Feinberg et al., 2000; Tobler et al., 2001; Kopp et al., 2004) . These effects are common for agonists acting at the benzodiazepine site, irrespective of whether they are benzodiazepines or non-benzodiazepine compounds, such as zolpidem or zopiclone (Aeschbach et al., 1994; Landolt et al., 2000) . Unlike benzodiazepines, honokiol induced a type of NREM sleep very similar to physiological NREM sleep, suggesting that honokiol is suitable for the treatment of insomnia.
Figure 4
Characteristics of sleep-wake episodes caused by honokiol and flumazenil. Total number and mean duration of wake, NREM and REM bouts in a 4 h period after the administration of honokiol (A) or flumazenil + honokiol (B). Changes in the numbers of NREM and REM sleep bouts for different ranges of episode duration during the 4 h following the administration of honokiol (C) or flumazenil + honokiol (D). Data shown are means Ϯ SEM (n = 5-6). *P < 0.05, **P < 0.01, significantly different from corresponding vehicle; two-tailed paired t-test.
The GABAA receptor forms a supramolecular complex with the benzodiazepine receptor and flumazenil is a specific antagonist of the benzodiazepine site on the GABAA receptor. Consistent with previous reports, we found that flumazenil caused no obvious effect on sleep when used alone under baseline conditions (Chu et al., 2007) . Honokiol-induced increases in NREM sleep were antagonized by flumazenil, suggesting that the benzodiazepine recognition site is one of the targets for the hypnotic action of honokiol.
Both diazepam and honokiol promote sleep, but diazepam suppresses the EEG delta activity of NREM sleep, whereas honokiol does not. Why the effects of honokiol on sleep are different from those of benzodiazepines still remains to be clarified. Probably, they act at different GABAA receptor subunits. Benzodiazepines have a similar affinity for a1, a2 and a3 subunits of GABAA receptors (Atack et al., 1999) . Mouse models carrying knock-in point mutations in GABAA receptor subunits have shown that suppression of delta activity by diazepam, is related to the a2 subunits (Kopp et al., 2004) , whereas the hypnotic action of diazepam is mediated by GABAA receptors containing a1 and/or a3 subtypes (Tobler et al., 2001; Kopp et al., 2003) . Honokiol enhanced chloride currents through GABAA receptors of seven different subunit compositions and was most effective at those containing a3b2 > a2b2 > a1b2 > a1b1 subunits (Taferner et al., 2011) , indicating that honokiol was more effective on a3 than a2-containing receptors, and thus may have less influence on EEG delta activity of NREM sleep. Taken together, these findings suggest that sleep promotion by benzodiazepines and honokiol is mediated by different GABAA receptor subunits.
The immediate early gene, c-Fos, is rapidly induced by many extracellular stimuli. Therefore, c-Fos expression has been proposed as a cellular marker for neuronal activity. Sleep-associated increases in the number of Fosimmunoreactive cells occur in the VLPO and the median preoptic nucleus (Sherin et al., 1996; Gong et al., 2000) . Activation of sleep-active neurons in the VLPO and median preoptic nucleus (data not shown) by the administration of honokiol supports our conclusion. Our patch clamping study showed that honokiol increased the firing rate of sleeppromoting neurons in the VLPO. A previous in vitro study has revealed two major types of neurons in the VLPO: the majority (69%) were inhibited by noradrenaline and a few were excited by noradrenaline (Gallopin et al., 2000) . The noradrenaline-inhibited neurons containing GABA are sleeppromoting neurons and project to major arousal systems, including the TMN (Sherin et al., 1996; Szymusiak et al., 1998; Gallopin et al., 2000) . The noradrenaline-excited VLPO neurons exhibit inhibitory postsynaptic currents mediated by GABA A receptors, indicating that they contain functional GABAA receptors (Liu et al., 2010) . There has been no report of the presence of non-GABA neurons in the VLPO. We therefore propose that the noradrenaline-excited VLPO neurons are GABA-containing neurons. When the organism is awake, the noradrenaline-inhibited VLPO neurons are probably under the inhibitory control of the noradrenalineexcited neurons. When honokiol acted upon the noradrenaline-excited neurons, this inhibitory control was removed, and firing rates of these noradrenaline-inhibited VLPO neurons were significantly increased. When excited, these VLPO neurons release GABA into the TMN, thus inhibiting the activity of this arousal-producing nucleus, inducing the onset of sleep. In this way, honokiol increases firing rates of sleep-promoting neurons in the VLPO, probably via Clinical and epidemiological studies have shown that sleep disturbance is tightly linked to major depression. Epidemiological studies showed a comparable prevalence of insomnia symptoms in patients with depression (Breslau et al., 1996) and about 41% of depressed patients have reported symptoms of insomnia (Stewart et al., 2006) . Sleep problems have also been identified as a prodromal feature of recurrent depressive episodes (Perlis et al., 1997) . In clinical samples, about three-quarters of all depressed patients complain of difficulty either in initiation or in maintaining sleep (Tsuno et al., 2005) . Honokiol can treat anxiety and depression models in mice (Kuribara et al., 2000; Xu et al., 2008) and we have found that honokiol increased NREM sleep, suggesting that honokiol may be useful as a sleep-promoting substance, especially for the insomnia that accompanies anxiety and depression. ) blocked the change in the number of Fos-positive cells in the VLPO cluster and TMN caused by honokiol (Hon; 20 mg·kg -1 ). Data shown are the means Ϯ SEM (n = 5-6). **P < 0.01 , significantly different from the vehicle group; one-way ANOVA, with Tukey's test.
In conclusion, honokiol increased the amount of NREM sleep and shortened sleep latency in mice. Unlike more commonly used sleeping pills, such as those containing benzodiazepines, honokiol did not alter the EEG power density, indicating that honokiol induces a type of NREM sleep similar to physiological NREM sleep and may be suitable for the treatment of insomnia. 
